公开(公告)号：US20070238770A1

公开(公告)日：2007-10-11

申请号：US11695124

申请日：2007-04-02

申请人： Jack Z. Gougoutas ,  Yongmei Wu ,  Soojin Kim ,  Dejah T. Petsch

发明人： Jack Z. Gougoutas ,  Yongmei Wu ,  Soojin Kim ,  Dejah T. Petsch

IPC分类号： A61K31/421 ,  C07D263/34

CPC分类号： C07D263/32

摘要： A process is provided for selectively preparing novel stable crystalline forms, namely selectively and consistently preparing Form N-1 of the free acid peliglitazar, Form N-2 of the free acid peliglitazar and Form P-1 of the L-lysine salt of the free acid peliglitazar. The process preferably employs solvent systems which produce crystals having suitable flow properties and desired particle size.Novel Form N-1 crystals of the free acid, Form N-2 crystals of the free acid, Form P-1 crystals of the L-lysine salt of the free acid, pharmaceutical compositions containing such novel forms and a method of treating diabetes, dyslipidemia and atherosclerosis employing such novel forms are also provided.

摘要翻译： 提供了一种选择性制备新的稳定结晶形式的方法，即选择性且一致地制备游离酸百日preparing唑形式的N-1，游离酸百日lit嗪的N-2型和游离酸性赖氨酸盐的L-赖氨酸盐形式P-1 酸苦瓜 该方法优选使用产生具有合适流动性和所需粒度的晶体的溶剂体系。 游离酸的新型N-1晶型，游离酸形式的N-2晶体，游离酸的L-赖氨酸盐的形式P-1晶体，含有这种新形式的药物组合物和治疗糖尿病的方法， 还提供了使用这种新型形式的血脂异常和动脉粥样硬化。

公开(公告)号：US06448401B1

公开(公告)日：2002-09-10

申请号：US09982199

申请日：2001-10-16

申请人： Chung-Pin Chen ,  Timothy Paul Connolly ,  Laxma Reddy Kolla ,  John D. Matiskella ,  Richard H. Mueller ,  Yadagiri Pendri ,  Dejah T. Petsch

发明人： Chung-Pin Chen ,  Timothy Paul Connolly ,  Laxma Reddy Kolla ,  John D. Matiskella ,  Richard H. Mueller ,  Yadagiri Pendri ,  Dejah T. Petsch

IPC分类号： C07F902

CPC分类号： C07F9/65583 ,  C07F9/6518

摘要： An improved process is provided for preparing water-soluble prodrugs of triazole antifungal compounds containing a secondary or tertiary hydroxyl group. More particularly, the improved process is directed toward preparation of water-soluble triazole antifungal compounds are provided having the general formula wherein A is the non-hydroxy portion of a triazole antifungal compound of the type containing a secondary or tertiary hydroxyl group and R and R1 are as defined in the specification.

摘要翻译： 提供了一种改进的方法，用于制备含有仲羟基或叔羟基的三唑抗真菌化合物的水溶性前药。 更具体地说，改进的方法是针对制备具有通式化合物的水溶性三唑抗真菌化合物A是含有仲羟基或叔羟基的三唑类抗真菌化合物的非羟基部分，R和R 1是 如说明书中所定义。